Document Detail


Challenges in clinical design of immunotherapy trials for malignant glioma.
MedLine Citation:
PMID:  19944979     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Glioblastoma multiforme (GBM) is the most common and lethal primary malignant brain tumor. The traditional treatments for GBM, including surgery, radiation, and chemotherapy, only modestly improve patient survival. Therefore, immunotherapy has emerged as a novel therapeutic modality. Immunotherapeutic strategies exploit the immune system's ability to recognize and mount a specific response against tumor cells, but not normal cells. Current immunotherapeutic approaches for glioma can be divided into 3 categories: immune priming (active immunotherapy), immunomodulation (passive immunotherapy), and adoptive immunotherapy. Immune priming sensitizes the patient's immune cells to tumor antigens using various vaccination protocols. In the case of immunomodulation, strategies are aimed at reducing suppressive cytokines in the tumor microenvironment or using immune molecules to specifically target tumor cells. Adoptive immunotherapy involves harvesting the patient's immune cells, followed by ex vivo activation and expansion before reinfusion. This article provides an overview of the interactions between the central nervous system and the immune system, and discusses the challenges facing current immunotherapeutic strategies.
Authors:
Cleo E Rolle; Sadhak Sengupta; Maciej S Lesniak
Related Documents :
11673539 - Nk- and cd8(+) t cell-mediated eradication of established tumors by peritumoral injecti...
8189059 - Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, a...
15054869 - B7-2 expression above a threshold elicits anti-tumor immunity as effective as interleuk...
20551919 - Potentiating cancer immunotherapy using an oncolytic virus.
14715709 - Steroidogenic acute regulatory (star)-directed immunotherapy protects against tumor gro...
8315389 - Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce...
8894249 - Interleukin-7 gene transfer in non-small-cell lung cancer decreases tumor proliferation...
22552839 - Mechanisms of apoptosis by the tumor suppressor par-4.
6096419 - Tumors of ceruminous glands.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Neurosurgery clinics of North America     Volume:  21     ISSN:  1558-1349     ISO Abbreviation:  Neurosurg. Clin. N. Am.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-11-30     Completed Date:  2009-12-24     Revised Date:  2011-08-01    
Medline Journal Info:
Nlm Unique ID:  9008004     Medline TA:  Neurosurg Clin N Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  201-14     Citation Subset:  IM    
Affiliation:
The University of Chicago Brain Tumor Center, The University of Chicago, 5841 South Maryland Avenue, MC 3026, Chicago, IL 60637, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Brain Neoplasms / therapy*
Clinical Trials as Topic*
Glioblastoma / therapy
Glioma / therapy*
Humans
Immunization, Passive
Immunotherapy* / methods
Immunotherapy, Active
Immunotherapy, Adoptive
Research Design*
Grant Support
ID/Acronym/Agency:
R01 CA138587-01A1/CA/NCI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Monitoring immune responses after glioma vaccine immunotherapy.
Next Document:  Safety and Short-term Outcomes following Controlled Blunt Microdissection Revascularization of Sympt...